NOMIC BIO INC.

Nomic (formerly nplex biosciences) is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. Nomic is a proteomics company with the highest-throughput platform for multiplexed protein quantification, and the Parker Institute for Cancer Immunotherapy. Nomic provides the nELISA platform, an ELISA system designed for high-throughput proteomics technology. Nomic has developed the most comprehensive solution for inflammation research that allows for the high-throughput quantification of hundreds of secreted proteins. Nomic is rapidly expanding its biological footprint to cover proteins across the entire proteome, unlocking new possibilities for diverse applications, uses cases, and disease areas. Nomic has secured a $42 million Series B round to bolster the expansion of its protein profiling platform. Nomic was founded to help scientific teams succeed in their mission to extend health spans. The nELISA platform allows us to understand, in an unbiased way; proteomics in relation to phenomics.